Xerostomia Therapeutics Market Size Worth USD 3.32 Billion by 2034 | CAGR 4.1%

The xerostomia therapeutics market size is expected to reach USD 3.32 billion by 2034, according to a new study by Polaris Market Research. The report “Xerostomia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Type (OTC and Prescription), By Product, By Distribution Channel, By Product Form, By Application, By End User, and By Region – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The xerostomia therapeutics market focuses on products designed to manage dry mouth. Dry mouth is a condition where the salivary glands do not produce enough saliva. This condition can cause discomfort and potentially lead to oral health problems. The market includes salivary stimulants, substitutes, and oral care products. The medication is aimed at relieving symptoms and improving oral health. The market growth is driven by factors such as an elderly population and increasing awareness about xerostomia. Also, the rising commonness of conditions such as Sjögren's syndrome and side effects from medications are fueling the market growth.

Xerostomia therapeutics market opportunities lie in the development of more effective and personalized treatments. These opportunities are due to advancements in salivary stimulants and substitutes. Trends include the growing demand for over-the-counter (OTC) solutions, innovations in oral healthcare products, and the expanding use of digital marketing strategies. Overall, the market demand is expected to grow steadily during the forecast period. The growth is fueled by the increasing number of affected individuals, the development of advanced treatment options, and expanding awareness globally.

Xerostomia Therapeutics Market Report Highlights

The OTC segment, based on type, dominated the market share in 2025. It is due to the widespread avaiability and affordability of products. These solutions offer quick relief for dry mouth symptoms. The prescription segment is registering the fastest growth. The growth is driven by increasing cases of chronic conditions such as Sjögren's syndrome. They require specialized treatments.
The saivary stimulants segment, by product, dominated the market share in 2025. They are effective in stimulating saliva production and addressing the core issue of xerostomia.
North America dominated the market revenue share in 2025. The dominance is due to the high prevaence of xerostomia and extensive healthcare access. Asia Pacific is the fastest-growing region due to increasing awareness of the condition and rising healthcare infrastructure. Also, the growing elderly population fuels the growth in this region.
The market comprises severa active companies offering various treatments for dry mouth. A few notable participants include Acacia Pharma; Church & Dwight Co., Inc.; Colgate-Palmolive Company; Forward Science; GlaxoSmithKline plc; Hikma Pharmaceuticals PLC; Lupin Pharmaceuticals, Inc.; Mission Pharmacal Company; OraCoat; Parnell Pharmaceuticals, Inc.; Pendopharm; Pfizer Inc.; Recordati Industria Chimica e Farmaceutica S.p.A; Sun Pharmaceutical Industries Ltd.; and Synedgen, Inc.

Where is the Market Headed?

The xerostomia therapeutics market is shifting toward more accessible and patient-friendly dry mouth treatments. These remedies include OTC sprays, gels, rinses, and saliva substitutes. They provide quick symptom relief. Companies are focusing on improving product effectiveness and developing longer-lasting oral care solutions. To expand market reach, vendors are strengthening distribution through pharmacies, e-commerce platforms, and healthcare partnerships. Xerostomia therapeutics are becoming important for improving oral health and managing dry mouth conditions in the aging population.

What does Xerostomia Therapeutics Market Report Reveals?

What is the global market size and CAGR for the market during 2026–2034?
Who are the key industry players? What is their relative position in terms of competitive positioning?
What factors are contributing largely to the industry expansion?
How do different distribution channels, such as retail pharmacies, hospital pharmacies, and online pharmacies, influence the market landscape?
How does the market differ in terms of type, product, distribution channel, product form, application, end user, and geography? Which is the leading product form?
What are the opportunities in different regional markets, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?
What are the emerging technologies and innovations in the market?

Request a free sample copy or read the full market insights : Xerostomia Therapeutics Market Report

Polaris Market Research has segmented the market report on the basis of type, product, distribution channel, product form, application, end user, and region:

By Type Outlook (Revenue – USD Billion, 2021–2034)

OTC
Prescription

By Product Outlook (Revenue – USD Billion, 2021–2034)

Saivary Stimulants
Saivary Substitutes
Dentifrices

By Distribution Channel Outlook (Revenue – USD Billion, 2021–2034)

Retai Pharmacies
Onine Pharmacies/E-Commerce
Hospita/Clinic Dispensing

By Product Form Outlook (Revenue – USD Billion, 2021–2034)

Sprays
Ges
Rinses/Mouthwashes
Lozenges

By End User Outlook (Revenue – USD Billion, 2021–2034)

Denta Clinics
Hospitas and Oncology Centers
Homecare Settings

By Application Outlook (Revenue – USD Billion, 2021–2034)

Radiation-Induced Xerostomia (RIX)
Sjögren’s Syndrome-Reated Xerostomia
Medication-Induced Xerostomia

By Regional Outlook (Revenue – USD Billion, 2021–2034)

North America
- US
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of Asia Pacific
Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa